CD274 and neoplasm: VEGF-targeted therapies may enhance the efficacy of PD-L1-targeted ICI by reversing VEGF mediated immunosuppression and promoting T cell infiltration into tumours [61], rationalising the combination of ICI with VEGF therapy.